Name: ABSA’s 1st Biosecurity Symposium
Start: 2021-04-20T00:00:00-05:00
End: 2021-04-23T23:59:59-05:00
Location: Renaissance Depot Hotel

DoD Researchers Collaborate on Universal Antibody Test for COVID-19

USAMRIID Gears Up to Fight COVID-19

by Global Biodefense Staff April 1, 2020, 2:19 pm
USAMRIID Resumes Full Operations Following Federal Select Agent Program Reinstatement

by Global Biodefense Staff April 1, 2020, 2:12 pm
USAMRIID: America’s Key Lab for Fighting Infectious Diseases Has Become a Pentagon Backwater

by Global Biodefense Staff March 21, 2020, 5:36 pm
PharmaJet Receives $9.6 Million Dollar Award to Support Next-Generation Needle-Free Delivery Devices

by Global Biodefense Staff March 17, 2020, 4:02 pm
Why is the Defense Department Withholding Funding for USAMRIID and CCDC Chemical Biological Center?

by Global Biodefense Staff February 5, 2020, 7:19 pm
First-Ever Therapeutic Antibody Cocktail for Sudan Virus Shows Promise in Animal Studies

by Global Biodefense Staff February 4, 2020, 4:22 pm
Henry Eigelsbach, Microbiologist Known for Tularemia Research, Dies at 100

by Global Biodefense Staff December 17, 2019, 10:01 am
CDC Approves Partial Resumption of USAMRIID Select Agent Research

by Global Biodefense Staff November 23, 2019, 3:07 pm
USAMRIID Study Leads to Approval of New Smallpox Vaccine

by Global Biodefense Staff October 20, 2019, 5:01 pm
Cutting Edge Chemical and Biological Defense Science: Hot Topics at CBD S&T 2019

by Saskia Popescu, PhD October 16, 2019, 8:59 am
Biosafety Levels in Laboratories – What is the Difference?

by Frankie Catalfumo September 22, 2019, 3:22 pm
Newsletter

Global Biodefense News

First Name

Last Name

Organization Type

Email address:

Don't worry, we don't spam
DoD Inspector General to Reevaluate Select Agent Facilities, Biosafety Oversight

by Stephanie Lizotte September 9, 2019, 3:23 pm
How Does USAMRIID Shut Down Impact Nation’s Bioterrorism Laboratory Response Network?

by Stephanie Lizotte August 13, 2019, 10:00 am
Lawmakers Seek Answers on USAMRIID Shutdown, BioDetection 21 Capabilities

by Global Biodefense Staff August 11, 2019, 6:18 pm

Congratulations. You've reached the end of the internet.

USAMRIID

DoD Researchers Collaborate on Universal Antibody Test for COVID-19

UT Austin Spearheads Scalable, ELISA Antibody Test for SARS-CoV-2

USAMRIID Scientists Engineer First Lethal Mouse Model for COVID-19

Health Security Today – 1 April 2020

USAMRIID Gears Up to Fight COVID-19

USAMRIID Resumes Full Operations Following Federal Select Agent Program Reinstatement

USAMRIID: America’s Key Lab for Fighting Infectious Diseases Has Become a Pentagon Backwater

PharmaJet Receives $9.6 Million Dollar Award to Support Next-Generation Needle-Free Delivery Devices

Why is the Defense Department Withholding Funding for USAMRIID and CCDC Chemical Biological Center?

First-Ever Therapeutic Antibody Cocktail for Sudan Virus Shows Promise in Animal Studies

Henry Eigelsbach, Microbiologist Known for Tularemia Research, Dies at 100

CDC Approves Partial Resumption of USAMRIID Select Agent Research

USAMRIID Study Leads to Approval of New Smallpox Vaccine

Cutting Edge Chemical and Biological Defense Science: Hot Topics at CBD S&T 2019

Biosafety Levels in Laboratories – What is the Difference?

DoD Inspector General to Reevaluate Select Agent Facilities, Biosafety Oversight

How Does USAMRIID Shut Down Impact Nation’s Bioterrorism Laboratory Response Network?

Lawmakers Seek Answers on USAMRIID Shutdown, BioDetection 21 Capabilities

Biodefense Headlines – 21 January 2021

First Cases of B.1.1.7 Variant COVID-19 Detected in Washington State

The Response Measures Database: Central Archive of COVID-19 Interventions

EU Initiative on Health Security Work Programme 2021

Rapid Identification of Ricin in Serum Samples Using LC–MS/MS

Dr. Fauci Makes First Appearance at Biden White House Press Briefing – Transcript

ASM Expresses Support for the Global Health Security Act of 2021

How and When Will Lower-Income Countries Gain Access to COVID-19 Vaccines?

OHDSI Awarded $10M FDA Contract to Monitor Safety and Effectiveness of Vaccines, Biologics

Neutralizing Norovirus: NIAID Monoclonal Antibodies Licensing Opportunity

NIAID Looks Ahead to Pan-Coronavirus Vaccine Candidates

DRIVE ReDIRECT: Program Seeks to Develop Countermeasures Against Chemical Threats

Emerging Infections Network – Managing Travelers Who Acquire Disease Abroad

Upcoming Events

Application Deadline: Expanding Existing Research Grants, CRADAs for Novel Coronavirus Response

Envisioning a Transformed Clinical Trials Enterprise for 2030 – Session 2

Systematizing the One Health Approach in Preparedness and Response Efforts for Infectious Disease Outbreaks

Envisioning a Transformed Clinical Trials Enterprise for 2030 – Session 3

ABSA’s 1st Biosecurity Symposium

Latest stories

Latest Articles